Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

LMNL6326 nominated as lead preclinical candidate for OXER1 antagonist development program, targeting the treatment of eosinophil-driven diseasesAdvancement of clinical trial application (CTA)

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,Canada ,Fairhaven ,Newfoundland ,Canadian ,Shrinal Inamdar ,Bruce Pritchard ,Kaitlin Gallagher ,Exchange Commission ,World Health Organisation ,Market Watch Research ,Securities Exchange ,Fairhaven Pharmaceuticals Inc ,Liminal Biosciences Inc ,Agonist Development Program ,Antagonist Development Program ,Prnewswire Liminal Biosciences Inc ,Nasdaq ,Chief Executive Officer ,Watch Research ,Future Market Insights ,Gary Bridger ,Interim Chief Scientific Officer ,Study Results ,About Liminal Biosciences ,Securities Act ,Securities Exchange Act ,Liminal Bioscience ,Nasdaq Listing Rule ,Nasdaq Capital Market ,Canadian Securities Administrators ,Annual Report ,Associate Director ,Investor Relations ,Media Contact ,Liminal ,Iosciences ,Rovides ,Update ,